POP-ART

A Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.

Ouvert à Paris depuis le : 14/10/2024
Ouvert à Saint-Cloud depuis le : 04/10/2024
Public cible : Adult
Phase : Phase I

Description de l'essai

Evaluate the safety and toxicity profile of PLX038 + Tuvusertib, and determine the maximum tolerated combination (MTC) and the recommended Phase 2 dose (RP2D).;Assess the efficacy of Tuvusertib + PLX038 in terms of overall response rate and confirm the safety and tolerability of the combination.

Url of the trial

Investigateur principal

FRANCOIS-CLEMENT BIDARD

Professeur - Médecin

Contacter